You are here: Industry Insights > Dupixent

News List

Sanofi's maintains its guidance for 2017 despite disappoiting Q3 results BioSpace.com
November 03, 2017
The launch of Dupixent, pediatric vaccine sales and continued growth in Sanofi’s multiple sclerosis franchise were the strongest revenue drivers in the third quarter, Chief Executive Officer Olivier Brandicourt announced Wednesday as the company revealed
Sanofi's Dupixent gets Europe eczema nod pharmatimes
September 29, 2017
The European Commission has given marketing authorisation for Dupixent (dupilumab), the first targeted biologic in Europe to treat the most common form of eczema.
EC grants marketing authorisation of Dupixent for atopic dermatitis europeanpharmaceuticalreview
September 29, 2017
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC has granted marketing authorisation for Dupixent for use in adults with moderate-to-severe atopic dermatitis…
Sanofi and Regeneron announce results for Dupixent (dupilumab) biospectrumasia
September 19, 2017
The results of the study was presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress
Dupixent severe asthma results should propel Sanofi, Regeneron drug to billions more in sales fiercepharma
September 12, 2017
Dupixent, the Sanofi and Regeneron drug already on a blockbuster arc in atopic dermatitis, has returned significant results in patients with severe asthma
Regeneron and Sanofi announce FDA approval of Dupixent cphi-online
March 29, 2017
Regeneron Pharmaceuticals and Sanofi have announced that the FDA has approved Dupixent (dupilumab) Injection, the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis.

Previous page 1 2 3 4 5 Next page